FORMATION OF ACTIVE METABOLITES OF ANTICONVULSANT DRUGS - A REVIEW OF THEIR PHARMACOKINETIC AND THEAPEUTIC SIGNIFICANCE

被引:33
作者
EADIE, MJ
机构
[1] Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Queensland, 4029, Clinical Science Building
关键词
D O I
10.2165/00003088-199121010-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
All of the commonly used anticonvulsant drugs, except possibly primidone, are cleared from the human body mainly by metabolism. The metabolites of phenytoin, phenobarbital and ethosuximide have so far not been shown to possess significant pharmacological activity. However, carbamazepine-10,11-epoxide, derived from carbamazepine, has anticonvulsant activity comparable with that of its progenitor, while oxcarbazepine, a new anticonvulsant congener of carbamazepine, is essentially a prodrug for its 10-hydroxy derivative. Valproic acid forms numerous metabolites through a variety of pathways; 2-en valproic acid, a beta-oxidation derivative, probably contributes to its anticonvulsant action, though the extent of the contribution is uncertain. Another metabolite, 4-en-valproic acid, has been considered a possible hepatotoxin and teratogen. N-Methyl-phenobarbital and primidone, though both anticonvulsants in their own right, are metabolised to phenobarbital, which probably mediates much of their antiseizure effect. Primidone also yields the weaker anticonvulsant phenylethylmalonamide. The various benzodiazepine anticonvulsants form numerous metabolites, some of which possess both antiseizure and other forms of pharmacological activity. As yet, there is little understanding of how best to interpret simultaneous plasma concentration measurements of anticonvulsant drug and its active metabolite (or metabolites) in the clinical situation, and the possible roles of anticonvulsant metabolites in the idiosyncratic toxicity of these drugs remain largely unexplored.
引用
收藏
页码:27 / 41
页数:15
相关论文
共 86 条
[1]  
ALBERT KS, 1974, RES COMMUN CHEM PATH, V9, P463
[2]   KINETICS OF DIPHENYLHYDANTOIN ELIMINATION IN RATS [J].
ASHLEY, JJ ;
LEVY, G .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1973, 1 (02) :99-102
[4]   PHENYLETHYLMALONAMIDE (PEMA) - IMPORTANT METABOLITE OF PRIMIDONE [J].
BAUMEL, IP ;
GALLAGHER, BB ;
MATTSON, RH .
ARCHIVES OF NEUROLOGY, 1972, 27 (01) :34-+
[5]   CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL EFFECTS OF CARBAMAZEPINE AND CARBAMAZEPINE-10,11-EPOXIDE - AN UPDATE [J].
BERTILSSON, L ;
TOMSON, T .
CLINICAL PHARMACOKINETICS, 1986, 11 (03) :177-198
[6]  
BOCHNER F, 1973, CLIN PHARMACOL THER, V14, P791
[7]  
BORONDY P, 1972, Federation Proceedings, V31, P582
[8]  
BOURGEOIS BFD, 1984, THER DRUG MONIT, V6, P259, DOI 10.1097/00007691-198409000-00001
[9]  
BOURGEOIS BFD, 1989, ANTIEPILEPTIC DRUGS, P401
[10]  
BUTLER TC, 1976, J PHARMACOL EXP THER, V199, P82